Liver Fibrosis Tool FIB-4: Strengths, Limits, and Evolution
Featured

Liver Fibrosis Tool FIB-4: Strengths, Limits, and Evolution

Gene Therapy

Tirzepatide and semaglutide have similar asthma risks
Gene Therapy
October 12, 2026

Tirzepatide and semaglutide have similar asthma risks

Tirzepatide and semaglutide have similar asthma risks in adults with type 2 diabetes and asthma.

Experts Redefine Obesity Treatment Success Metrics
Gene Therapy
October 6, 2026

Experts Redefine Obesity Treatment Success Metrics

Experts redefine obesity treatment success metrics to include metabolic health and body composition improvements in...

Actress gains strength with new workout routine
Gene Therapy
September 29, 2026

Actress gains strength with new workout routine

Actress Laysla De Oliveira gains strength with new workout routine and builds confidence in the...

NF Research

Read our latest NF Research articles.

Study finds warfarin may suit low-risk AF patients when DOACs
NF Research October 13, 2026

Study finds warfarin may suit low-risk AF patients when DOACs

Study suggests warfarin may be a viable option for low-risk atrial fibrillation patients when cost...

Blood Test May Detect Spine Damage Early
NF Research October 10, 2026

Blood Test May Detect Spine Damage Early

Blood test may detect spine damage early in adults with ankylosing spondylitis, achieving strong accuracy.

Patient Briefs

Trial Moves

All Posts

Liver Fibrosis Tool FIB-4: Strengths, Limits, and Evolution
NF Research

Liver Fibrosis Tool FIB-4: Strengths, Limits, and Evolution

Strengths, limits, and evolution of the FIB-4 liver fibrosis tool, a noninvasive method for assessing liver health.

Study finds warfarin may suit low-risk AF patients when DOACs
NF Research

Study finds warfarin may suit low-risk AF patients when DOACs

Study suggests warfarin may be a viable option for low-risk atrial fibrillation patients when cost concerns limit DOAC use, with...

Tirzepatide and semaglutide have similar asthma risks
Gene Therapy

Tirzepatide and semaglutide have similar asthma risks

Tirzepatide and semaglutide have similar asthma risks in adults with type 2 diabetes and asthma.

U.S. Alopecia Guidelines Name Oral JAK Inhibitors First-Line
Tumor Watch

U.S. Alopecia Guidelines Name Oral JAK Inhibitors First-Line

U.S. alopecia guidelines name oral JAK inhibitors first-line therapy, recommends FDA-approved drugs for severe cases with NAAF and AHRS consensus...

Blood Test May Detect Spine Damage Early
NF Research

Blood Test May Detect Spine Damage Early

Blood test may detect spine damage early in adults with ankylosing spondylitis, achieving strong accuracy.

Teachers and pediatricians face similar challenges
Tumor Watch

Teachers and pediatricians face similar challenges

Teachers and pediatricians face similar challenges in underfunded schools and healthcare systems, impacting their ability to help those in need.

FDA approves new Parkinsons disease treatment
Tumor Watch

FDA approves new Parkinsons disease treatment

FDA approves new treatment for Parkinson's disease, offering a novel option for adults with the condition.

Epilepsy Patients Handle Menopause Through Adaptive Care
Trial Moves

Epilepsy Patients Handle Menopause Through Adaptive Care

Epilepsy menopause care strategies through adaptive clinical pathways, guiding clinicians in managing hormonal fluctuations that may increase seizure ri

Experts Redefine Obesity Treatment Success Metrics
Gene Therapy

Experts Redefine Obesity Treatment Success Metrics

Experts redefine obesity treatment success metrics to include metabolic health and body composition improvements in obesity treatment.

New fitness program offers personalized strength training for muscle growth
Patient Briefs

New fitness program offers personalized strength training for muscle growth

Build & Burn, a four-week fitness program offering personalized strength training for muscle growth, fat reduction, and better movement efficiency...

Show More →